Buntanetap is a small molecule commercialized by Annovis Bio, with a leading Phase III program in Parkinson’s Disease. According to Globaldata, it is involved in 15 clinical trials, of which 8 were completed, 4 are ongoing, 2 are planned, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Buntanetap’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for Buntanetap is expected to reach an annual total of $235 mn by 2035 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Buntanetap Overview

Buntanetap (ANVS-401 (Posiphen)) is under development for the treatment of Alzheimer's disease, Parkinson's disease, Alzheimer's disease in Down syndrome , frontotemporal dementia (FTD), chronic traumatic encephalopathy (CTE) and Lewy body dementia. The drug candidate is the enantiomer of phenserine. It is administered through oral route. It acts by targeting amyloid precursor protein (APP), tau and alpha-synuclein.

It was also under development for the treatment of Huntington’s disease and traumatic brain injury. 

Annovis Bio Overview

Annovis Bio is a clinical-stage drug platform company that carries out the development of novel drugs for the treatment of various diseases. The company’s pipeline products comprise buntanetap, to treat Parkinson’s disease (PD), Alzheimer’s disease (AD), and other chronic neurodegenerative diseases; ANVS405, to treat traumatic brain injury (TBI) and stroke; ANVS301, to treat advanced Alzheimer’s disease. It provides drug candidates in oral and injectable forms. Annovis Bio also carries out preclinical animal studies and clinical trials. The company collaborates with contractor laboratories, independent contractors and contract research organizations. Annovis Bio is headquartered in Berwyn, Pennsylvania, the US.

The operating loss of the company was US$25.5 million in FY2022, compared to an operating loss of US$14.5 million in FY2021. The net loss of the company was US$25.3 million in FY2022, compared to a net loss of US$14.5 million in FY2021.

For a complete picture of Buntanetap’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 7 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.